XML 67 R53.htm IDEA: XBRL DOCUMENT v3.3.1.900

Long-term incentive compensation and shareholders' equity (Tables)

12 Months Ended

Dec. 31, 2015

Share Based Compensation [Abstract]

Summary of Status of Awards Under Stock-Based Compensation Plans and Agreements

A combined summary of the status of the Company’s stock-settled awards under the 2011 Plan, including base shares for stock-settled stock appreciation rights and stock-settled stock unit awards is as follows:

		Year ended December 31, 2015
		Stock appreciation rights												Stock units
						Weighted				Weighted								Weighted
						average				average								average
						exercise				remaining								remaining
		Awards				price				contractual life				Awards				contractual life
Outstanding at beginning of year			10,585,172			$	53.21								921,898
Granted			993,953				81.22								279,485
Exercised			(2,409,579	)			41.62								(348,127	)
Cancelled			(635,985	)			62.42								(88,196	)
Outstanding at end of period			8,533,561			$	59.05				2.3				765,060				0.4
Exercisable at end of period			2,856,959			$	47.88				1.2				—				—
Weighted-average fair value of grants in 2015		$	17.97											$	80.25
Weighted-average fair value of grants in 2014		$	16.41											$	72.24
Weighted-average fair value of grants in 2013		$	13.47											$	58.90

Summary of Range of Exercise Prices

		Awards				Weighted average				Awards				Weighted average
Range of SSAR base prices		outstanding				exercise price				exercisable				exercise price
$30.01–$40.00			369,301				36.56				358,969				36.54
$40.01–$50.00			1,437,708				43.02				1,390,300				42.86
$50.01–$60.00			4,143,205				57.54				843,384				55.30
$60.01–$70.00			1,293,564				68.12				216,000				65.08
$70.01–$80.00			588,733				73.80				48,306				70.31
$80.01–$90.00			701,050				83.60				—				—
Total			8,533,561			$	59.05				2,856,959			$	47.88

Summary of Weighted Average Valuation Inputs

A summary of the weighted average valuation inputs described above used for estimating the grant-date fair value of stock-settled stock appreciation rights awards granted in the periods indicated is as follows:

		Year ended December 31,
		2015				2014				2013
Expected term		4.1 years				4.2 years				4.1 years
Expected volatility			24.6	%			25.8	%			27.2	%
Expected dividend yield			0.0	%			0.0	%			0.0	%
Risk-free interest rate			1.5	%			1.5	%			0.7	%

Effects of Changes in DaVita Inc's Ownership Interest on Company's Equity

The effects of changes in DaVita HealthCare Partners Inc.’s ownership interest on the Company’s equity are as follows:

		Year ended December 31,
		2015				2014				2013
Net income attributable to DaVita HealthCare Partners Inc.		$	269,732			$	723,114			$	633,446
Increase (decrease) in paid-in capital for sales of    noncontrolling interest			—				355				(1,442	)
Decrease in paid-in capital for the purchase of noncontrolling    interests			(55,826	)			(5,357	)			(3,119	)
Net transfer to noncontrolling interests			(55,826	)			(5,002	)			(4,561	)
Change from net income attributable to DaVita HealthCare    Partners Inc. and transfers to noncontrolling interests		$	213,906			$	718,112			$	628,885

X

- Definition

Net Effect Of Transfers From (To) Noncontrolling Interests on Stock Holders Equity Disclosure

+ References

No definition available.

+ Details

Name:	dva_NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock
Namespace Prefix:	dva_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of share-based compensation plans that may be presented in a single table for outstanding, vested and expected to vest, and exercisable awards. The information that may be disclosed in this table may include, but is not limited to, number of shares, weighted average exercise price, weighted average remaining contractual life, and aggregate intrinsic value.

+ References

No definition available.

+ Details

Name:	us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name:	us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name:	us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_ShareBasedCompensationAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration